ICU Medical (NASDAQ:ICUI) Updates FY 2026 Earnings Guidance

ICU Medical (NASDAQ:ICUI) updated its FY 2026 earnings guidance on Thursday morning. The company provided EPS guidance of 8.600-9.000 for the period, compared to the consensus EPS estimate of 7.830. The company issued revenue guidance of -.

Analysts Set New Price Targets

ICUI has been the subject of a number of research analyst reports. Jefferies Financial Group upgraded ICU Medical to a “strong-buy” rating in a report on Thursday, May 7th. Needham & Company LLC raised shares of ICU Medical from a “hold” rating to a “buy” rating and set a $165.00 price objective for the company in a report on Wednesday, May 27th. KeyCorp increased their target price on shares of ICU Medical from $164.00 to $182.00 and gave the stock an “overweight” rating in a report on Tuesday, July 21st. Weiss Ratings upgraded shares of ICU Medical from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Thursday, July 23rd. Finally, BTIG Research began coverage on shares of ICU Medical in a research report on Monday, June 15th. They set a “buy” rating and a $170.00 price objective for the company. Two analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $172.00.

ICU Medical Stock Performance

Shares of ICU Medical stock traded down $0.03 during trading on Thursday, hitting $166.37. 359,613 shares of the stock were exchanged, compared to its average volume of 291,923. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.17 and a current ratio of 2.34. ICU Medical has a 12 month low of $107.00 and a 12 month high of $176.27. The stock’s fifty day moving average is $150.11 and its 200 day moving average is $140.65. The stock has a market cap of $4.16 billion, a PE ratio of 89.93, a P/E/G ratio of 2.40 and a beta of 0.74.

ICU Medical (NASDAQ:ICUI) last issued its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $2.37 earnings per share for the quarter, beating the consensus estimate of $1.91 by $0.46. The firm had revenue of $547.88 million for the quarter, compared to the consensus estimate of $533.44 million. ICU Medical had a net margin of 2.15% and a return on equity of 7.50%. ICU Medical has set its FY 2026 guidance at 8.600-9.000 EPS. As a group, sell-side analysts anticipate that ICU Medical will post 6.51 EPS for the current year.

Insider Buying and Selling

In related news, VP Virginia Ruth Sanzone sold 2,447 shares of the firm’s stock in a transaction that occurred on Thursday, May 14th. The stock was sold at an average price of $124.08, for a total value of $303,623.76. Following the sale, the vice president directly owned 19,460 shares in the company, valued at $2,414,596.80. This trade represents a 11.17% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director David C. Greenberg sold 2,424 shares of ICU Medical stock in a transaction on Tuesday, May 12th. The shares were sold at an average price of $122.91, for a total value of $297,933.84. Following the sale, the director directly owned 7,960 shares in the company, valued at $978,363.60. The trade was a 23.34% decrease in their position. The disclosure for this sale is available in the SEC filing. Corporate insiders own 2.10% of the company’s stock.

Hedge Funds Weigh In On ICU Medical

Large investors have recently bought and sold shares of the stock. Smartleaf Asset Management LLC raised its position in shares of ICU Medical by 11.6% during the 2nd quarter. Smartleaf Asset Management LLC now owns 969 shares of the medical instruments supplier’s stock worth $128,000 after buying an additional 101 shares in the last quarter. Headlands Technologies LLC bought a new stake in ICU Medical during the second quarter worth approximately $177,000. O Shaughnessy Asset Management LLC acquired a new stake in ICU Medical in the fourth quarter worth approximately $203,000. Panagora Asset Management Inc. bought a new position in ICU Medical during the 4th quarter valued at $205,000. Finally, Janney Montgomery Scott LLC acquired a new position in shares of ICU Medical during the 4th quarter valued at $216,000. Institutional investors and hedge funds own 96.10% of the company’s stock.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.